동물 위식도역류질환 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 제품별, 동물 종류별, 투여 경로별, 유통 채널별, 지역별 및 경쟁(2021-2031년)

The Global Animal Gastroesophageal Reflux Disease Market is projected to expand from USD 3.56 Billion in 2025 to USD 5.92 Billion by 2031, achieving a CAGR of 8.85%. This market sector encompasses specialized diagnostic tools and pharmaceutical treatments, such as proton pump inhibitors and H2 receptor antagonists, specifically formulated to alleviate acid reflux in companion animals. Growth is primarily propelled by the pet humanization trend, which has fostered a greater willingness among owners to fund advanced veterinary healthcare, alongside an increasing prevalence of gastrointestinal ailments in aging pet populations. As highlighted by the American Pet Products Association in 2024, total U.S. pet industry spending hit $152 billion, with $39.8 billion directed toward veterinary care and products, demonstrating the substantial financial dedication owners have toward animal well-being.

However, the high expenses linked to long-term veterinary care and specialized diagnostic procedures pose a significant obstacle to market progression. These substantial costs can establish a barrier for budget-conscious pet owners, potentially restricting the broad implementation of thorough treatment regimens and decelerating the sector's overall growth rate. Consequently, price sensitivity remains a critical challenge that could impede the widespread adoption of comprehensive management plans for animal gastroesophageal reflux disease, thereby slowing the expansion of the market.

Market Driver

The surge in global pet ownership and the trend of humanization are fundamentally transforming the demand for specialized veterinary therapeutics, especially for chronic ailments like gastroesophageal reflux disease. As owners increasingly regard companion animals as family members, they are more likely to seek immediate veterinary care for symptoms of distress, such as regurgitation or dysphagia, rather than ignoring them. This emotional connection drives higher utilization of diagnostic and pharmaceutical solutions, broadening the market for acid suppressants. Data from UK Pet Food's 'Pet Population 2024' report indicates that roughly 17.2 million households in the United Kingdom own a pet, accounting for 60 percent of the population, providing a vast and growing patient base for managing chronic digestive health conditions.

Additionally, the increasing prevalence of diet-induced and obesity-related reflux acts as a pivotal clinical catalyst for market growth, given that excess weight severely impairs gastrointestinal function. Obesity elevates intra-abdominal pressure, resulting in sphincter dysfunction and chronic acid reflux that requires ongoing pharmacological treatment. Despite this, early treatment is often hindered by a lack of owner awareness; the Association for Pet Obesity Prevention's '2023 National Pet Weight and Nutrition Survey' from May 2024 noted that only 17 percent of dog owners identified their pets as overweight, contrasting sharply with clinical prevalence. This gap highlights significant latent market potential as diagnostic awareness rises, further supported by the sector's strong economic foundation, evidenced by Zoetis reporting full-year 2023 revenue of $8.5 billion in 2024.

Market Challenge

The substantial expenses required for long-term veterinary management and specialized diagnostic procedures represent a major hurdle to the expansion of the Global Animal Gastroesophageal Reflux Disease Market. Accurate diagnosis often demands costly interventions like endoscopy or specialized pH monitoring, while effective treatment relies on the chronic administration of medications such as proton pump inhibitors. These financial requirements form a formidable barrier for price-sensitive pet owners, frequently resulting in the postponement of essential diagnostic screenings or the cessation of maintenance therapies, which ultimately reduces potential market revenue as segments of the pet population remain untreated.

This financial strain is reflected in recent industry metrics showing that escalating prices are influencing client behavior. According to the American Veterinary Medical Association, data analyzed in 2024 from thousands of practices indicated a 2.3% decline in patient visits compared to the previous year, a trend largely driven by rising service costs compelling budget-conscious owners to restrict veterinary visits. This decrease in clinical traffic directly impedes the market by reducing opportunities for veterinarians to diagnose and treat complex gastrointestinal disorders, thereby stalling the wider uptake of reflux disease therapeutics.

Market Trends

The adoption of Brachycephalic-Focused Treatment Protocols is swiftly altering clinical standards within the Global Animal Gastroesophageal Reflux Disease Market. Veterinarians are increasingly associating Brachycephalic Obstructive Airway Syndrome (BOAS) with hiatal hernias and chronic acid reflux, leading to specialized therapeutic regimens that integrate surgical airway correction with long-term acid suppression. This breed-specific approach is fueled by the enduring popularity of flat-faced dogs, which genetically demand significantly more gastrointestinal care than other breeds. As reported by the American Kennel Club in March 2024, French Bulldogs remained the most registered breed with 98,500 registrations, guaranteeing a steady stream of patients needing these targeted reflux management strategies.

Concurrently, the proliferation of Therapeutic Gastrointestinal Diets and Nutrition is transforming management strategies by emphasizing multimodal conservative therapy over sole reliance on pharmaceuticals. Industry leaders are vigorously expanding their offerings of highly digestible, low-fat prescription diets and microbiome-enhancing supplements aimed at alleviating reflux symptoms and boosting esophageal motility without the side effects associated with chronic medication. This movement mirrors a wider consumer shift toward functional wellness products serving as complementary treatments to standard proton pump inhibitors. According to Petfood Industry in February 2024, Purina Pro Plan Veterinary Supplement sales surged by 22.6% in 2023, highlighting the swift commercial adoption of nutritional interventions for digestive health.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale S.A.
• Boehringer Ingelheim International GmbH
• McNeil Consumer Pharmaceuticals Co.
• BioZyme, Inc.
• Annamaet Petfoods Inc.
• Hill's Pet Nutrition, Inc.
• Blue Buffalo Co., Ltd.

Report Scope

In this report, the Global Animal Gastroesophageal Reflux Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Gastroesophageal Reflux Disease Market, By Product

• Diagnostics
• Treatment
• Others

Animal Gastroesophageal Reflux Disease Market, By Animal Type

• Companion Animals
• Livestock Animals

Animal Gastroesophageal Reflux Disease Market, By Route of Administration

• Oral
• Injectable

Animal Gastroesophageal Reflux Disease Market, By Distribution Channel

• Veterinary hospitals & clinics
• Retail Pharmacies
• E-commerce

Animal Gastroesophageal Reflux Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Gastroesophageal Reflux Disease Market.

Available Customizations:

Global Animal Gastroesophageal Reflux Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Gastroesophageal Reflux Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Diagnostics, Treatment, Others)
  • 5.2.2. By Animal Type (Companion Animals, Livestock Animals)
  • 5.2.3. By Route of Administration (Oral, Injectable)
  • 5.2.4. By Distribution Channel (Veterinary hospitals & clinics, Retail Pharmacies, E-commerce)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Animal Gastroesophageal Reflux Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Animal Gastroesophageal Reflux Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Animal Gastroesophageal Reflux Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Animal Gastroesophageal Reflux Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Animal Gastroesophageal Reflux Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Gastroesophageal Reflux Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Elanco Animal Health Inc.
• 15.4. Ceva Sante Animale S.A.
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. McNeil Consumer Pharmaceuticals Co.
• 15.7. BioZyme, Inc.
• 15.8. Annamaet Petfoods Inc.
• 15.9. Hill's Pet Nutrition, Inc.
• 15.10. Blue Buffalo Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer